Metraipolis › archive › dc_02fc072d042d

Ipilimumab and nivolumab for cancer treatment: a pharmacovigilance study based on the FDA adverse event reporting system database — Europe PMC PMID:42395180

Source: Europe PMC (en)
Original: https://europepmc.org/article/MED/42395180
DOI: 10.3389/fendo.2026.1786504
License (as archived): solo-consultazione
Archived: 2026-10-08T03:16:43.824Z
SHA-256 of the archived text: 87842466aca1c0950fe45e272e626ce623702ae66ed7f063ebd8a87dfb8ee643
Stable URL of this page: https://metraipolis.com/documento/dc_02fc072d042d

How to cite

Ipilimumab and nivolumab for cancer treatment: a pharmacovigilance study based on the FDA adverse event reporting system database — Europe PMC PMID:42395180 — Europe PMC (en), https://europepmc.org/article/MED/42395180 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_02fc072d042d (Metraipolis archive dc_02fc072d042d, sha256 87842466aca1c0950fe45e272e626ce623702ae66ed7f063ebd8a87dfb8ee643)

BibTeX

@misc{dc02fc072d042d,
  title = {Ipilimumab and nivolumab for cancer treatment: a pharmacovigilance study based on the FDA adverse event reporting system database — Europe PMC PMID:42395180},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42395180},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_02fc072d042d; sha256 87842466aca1c0950fe45e272e626ce623702ae66ed7f063ebd8a87dfb8ee643},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42395180. Agents can read the archived copy with the MCP tool read_document.